BLRX - BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer

BioLineRx (BLRX) gains 22% premarket after announcing results from its COMBAT/KEYNOTE-202 clinical study evaluating motixafortide (BL-8040) in combination with Merck's (MRK) KEYTRUDA (pembrolizumab) and chemotherapy in patients with second-line stage IV pancreatic ductal adenocarcinoma ((PDAC)).A total of 43 patients were enrolled in the triple combination arm. The primary endpoint is the objective response rate ((ORR)); secondary endpoints include confirmed objective response rate (cORR), overall survival ((OS)), progression free survival ((PFS)), and disease control rate ((DCR)).Data are summarized below for the evaluable patients in the study (n=38).Median OS was 6.5 months compared to historical data of 4.7 months.Median PFS in COMBAT/KEYNOTE study was 4.0 months vs. historical results of 2.7-3.1 months.cORR, ORR and DCR was 13.2%, 21.2% and 63.2%, respectively in triple combination arm vs. 7.7%, 16% and 29-52% historical data.The combination was generally well tolerated, with a safety profile consistent with the individual safety profile of each component alone.The results showed substantial improvement

For further details see:

BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer